Abstract
Vanita R. Aroda, Billy S. Collins, Robert A. Gabbay, Jennifer Green, Nisa M. Maruthur, Sylvia E. Rosas, Stefano Del Prato, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Tsvetalina Tankova, Apostolos Tsapas, John B. Buse
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
Unlocking Potential: Personalized Lifestyle Therapy for Type 2 Diabetes Through a Predictive Algorithm-Driven Digital Therapeutic
2024 · 0 citations
Glucose in Motion: Characterizing Temporal Patterns in Real-World Glycemic Control in a Large Observational Cohort
2026 · 0 citations
A Selective Cullin 3 RING E3 Ligase Inhibitor Attenuates Hyperglycemia via Dual Insulin Sensitizing and Insulinotropic Action
2026 · 0 citations
Shared decision making in endocrinology: present and future directions
10.1016/s2213-8587(15)00468-4 · 2016
6. Glycemic targets: Standards of Medical Care in Diabetes—2022
10.2337/dc22-s006 · 2022
Management of hyperglycaemia in type 2 diabetes: a patient-centred approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
10.1007/s00125-012-2534-0 · 2012
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes
10.1007/s00125-014-3460-0 · 2015
Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
10.1007/s00125-018-4729-5 · 2018
2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
10.1007/s00125-019-05039-w · 2020
Development of the instrument to assess the credibility of effect modification analyses (ICEMAN) in randomized controlled trials and meta-analyses
10.1503/cmaj.200077 · 2020
How to use a subgroup analysis: users’ guide to the medical literature
10.1001/jama.2013.285063 · 2014
GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations
10.1016/j.jclinepi.2012.03.013 · 2013
GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions
10.1016/j.jclinepi.2019.10.014 · 2020
Reappraisal of the efficacy of intensive glycaemic control on microvascular complications in patients with type 2 diabetes: a meta-analysis of randomised control-trials
10.1016/j.therap.2021.10.002 · 2021
Long-term follow-up of intensive glycaemic control on renal outcomes in the Veterans Affairs Diabetes Trial (VADT)
10.1007/s00125-017-4473-2 · 2018
Historical HbA1c values may explain the type 2 diabetes legacy effect: UKPDS 88
10.2337/dc20-2439 · 2021
A1C targets should be personalized to maximize benefits while limiting risks
10.2337/dci18-0018 · 2018
Adults with early-onset type 2 diabetes (aged 18-39 years) are severely underrepresented in diabetes clinical research trials
10.1007/s00125-020-05174-9 · 2020
9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes–2022
10.2337/dc22-s009 · 2022
Intensive glycemic control and macrovascular, microvascular, hypoglycemia complications and mortality in older (age ≥60years) or frail adults with type 2 diabetes: a systematic review and meta-analysis from randomized controlled trial and observation studies
10.1080/17446651.2022.2079495 · 2022
The use of language in diabetes care and education
10.2337/dci17-0041 · 2017
Diabetes self-management education and support in adults with type 2 diabetes: a consensus report of the American Diabetes Association, the Association of Diabetes Care & Education Specialists, the Academy of Nutrition and Dietetics, the American Academy of Family Physicians, the American Academy of PAs, the American Association of Nurse Practitioners, and the American Pharmacists Association
10.2337/dci20-0023 · 2020
2022 National standards for diabetes self-management education and support
10.2337/dc21-2396 · 2022
Unresolved referenced work
Kept as external metadata until matched
5. Facilitating behavior change and well-being to improve health outcomes: Standards of Medical Care in Diabetes–2022
10.2337/dc22-s005 · 2022
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
Diabetes self-management education for adults with type 2 diabetes mellitus: a systematic review of the effect on glycemic control
10.1016/j.pec.2015.11.003 · 2016
Behavioral programs for type 2 diabetes mellitus: a systematic review and network meta-analysis
10.7326/m15-1400 · 2015
Theory-based self-management educational interventions on patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
10.1111/jan.13163 · 2017
Effectiveness of group-based self-management education for individuals with type 2 diabetes: a systematic review with meta-analyses and meta-regression
10.1111/dme.13340 · 2017
Diabetes self-management education reduces risk of all-cause mortality in type 2 diabetes patients: a systematic review and meta-analysis
10.1007/s12020-016-1168-2 · 2017
Diabetes structured self-management education programmes: a narrative review and current innovations
10.1016/s2213-8587(17)30239-5 · 2018
Supported self-management for people with type 2 diabetes: a meta-review of quantitative systematic reviews
10.1136/bmjopen-2018-024262 · 2018
Prevalence of type 2 diabetes in psychiatric disorders: an umbrella review with meta-analysis of 245 observational studies from 32 systematic reviews
10.1007/s00125-021-05609-x · 2022
Web-based interventions for dietary behavior in adults with type 2 diabetes: systematic review of randomized controlled trials
10.2196/16437 · 2020
Impact of DSMES app interventions on medication adherence in type 2 diabetes mellitus: systematic review and meta-analysis
10.1136/bmjhci-2020-100291 · 2021
The impact of a self-management educational program coordinated through WhatsApp on diabetes control
10.18549/pharmpract.2020.2.1841 · 2020
Use of MyDesmond digital education programme to support self-management in people with type 2 diabetes during the COVID-19 pandemic
10.1111/dme.14469 · 2021
Digital coaching strategies to facilitate behavioral change in type 2 diabetes: a systematic review
10.1210/clinem/dgaa850 · 2021
A novel user utility score for diabetes management using tailored mobile coaching: secondary analysis of a randomized controlled trial
10.2196/17573 · 2021
Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables
10.1016/s2213-8587(18)30051-2 · 2018
Validation of the classification for type 2 diabetes into five subgroups: a report from the ORIGIN trial
10.1007/s00125-021-05567-4 · 2022
Health information technology and digital innovation for national learning health and care systems
10.1016/s2589-7500(21)00005-4 · doi-reference
Advancing the learning health system
10.1056/nejmp2103872 · doi-reference
Creating a learning health system through rapid-cycle, randomized testing
10.1056/nejmsb1900856 · doi-reference
A global perspective on the issue of access to insulin
10.1007/s00125-020-05375-2 · doi-reference
Insulin discovery: a pivotal point in medical history
10.1016/j.metabol.2021.154941 · doi-reference
IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045
10.1016/j.diabres.2021.109119 · doi-reference
The Lancet Commission on diabetes: using data to transform diabetes care and patient lives
10.1016/s0140-6736(20)32374-6 · doi-reference
Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: a randomized clinical trial
10.1001/jama.2021.7444 · doi-reference
The impact of flash glucose monitoring on glycaemic control as measured by HbA1c: a meta-analysis of clinical trials and real-world observational studies
10.1007/s13300-019-00720-0 · doi-reference
Impact of technology on glycaemic control in type 2 diabetes: A meta-analysis of randomized trials on continuous glucose monitoring and continuous subcutaneous insulin infusion
10.1111/dom.13845 · doi-reference
Effect of telemetric interventions on glycated hemoglobin A1c and management of type 2 diabetes mellitus: systematic meta-review
10.2196/23252 · doi-reference
Efficacy and safety of basal insulin/GLP-1 receptor agonist used in combination for type 2 diabetes management
10.1177/0897190018764984 · doi-reference
Real-world clinical outcomes and costs in type 2 diabetes mellitus patients after initiation of insulin therapy: a German claims data analysis
10.1016/j.diabres.2021.108734 · doi-reference
Lower rates of hypoglycemia during maintenance treatment with insulin degludec/insulin aspart versus biphasic insulin aspart 30: a combined analysis of two phase 3a studies in type 2 diabetes
10.1111/1753-0407.12355 · doi-reference
Rapid-acting insulin analogues versus regular human insulin: a meta-analysis of effects on glycemic control in patients with diabetes
10.1007/s13300-019-00732-w · doi-reference
Addition of rapid-acting insulin to basal insulin therapy in type 2 diabetes: indications and modalities
10.1016/s1262-3636(07)70241-0 · doi-reference
Comparative benefits and harms of basal insulin analogues for type 2 diabetes: a systematic review and network meta-analysis
10.7326/m18-0443 · doi-reference
A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control
10.1111/1753-0407.12351 · doi-reference
A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea
10.1111/dom.12234 · doi-reference
Comparison of vildagliptin as an add-on therapy and sulfonylurea dose-increasing therapy in patients with inadequately controlled type 2 diabetes using metformin and sulfonylurea (VISUAL study): a randomized trial
10.1016/j.diabres.2015.04.019 · doi-reference
Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea
10.1111/dom.12229 · doi-reference
Triple therapy combinations for the treatment of type 2 diabetes–a network meta-analysis
10.1016/j.diabres.2016.04.037 · doi-reference
Triple therapy in type 2 diabetes; a systematic review and network meta-analysis
10.7717/peerj.1461 · doi-reference
Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials
10.1111/dom.13185 · doi-reference
Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in type 2 diabetes: a network meta-analysis
10.1111/dme.12837 · doi-reference
Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study
10.1016/s2213-8587(16)30057-2 · doi-reference
Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes
10.1111/dom.14670 · doi-reference
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
10.1016/s0140-6736(19)31149-3 · doi-reference
Liraglutide and cardiovascular outcomes in type 2 diabetes
10.1056/nejmoa1603827 · doi-reference
Cardiovascular, renal, and metabolic outcomes of dapagliflozin versus placebo in a primary cardiovascular prevention cohort: analyses from DECLARE-TIMI 58
10.2337/dc20-2492 · doi-reference
The Look AHEAD trial: a review and discussion of its outcomes
10.1007/s13668-014-0099-x · doi-reference
Nutrition therapy for adults with diabetes or prediabetes: a consensus report
10.2337/dci19-0014 · doi-reference
Magnitude of cognitive dysfunction in adults with type 2 diabetes: a meta-analysis of six cognitive domains and the most frequently reported neuropsychological tests within domains
10.1017/s1355617713001483 · doi-reference
Type 2 diabetes and cognitive dysfunction–towards effective management of both comorbidities
10.1016/s2213-8587(20)30118-2 · doi-reference
Cardiovascular risk assessment scores for people with diabetes: a systematic review
10.1007/s00125-009-1454-0 · doi-reference
Team-based care to improve diabetes management: a community guide meta-analysis
10.1016/j.amepre.2019.02.005 · doi-reference
The impact of empagliflozin on obstructive sleep apnea and cardiovascular and renal outcomes: an exploratory analysis of the EMPA-REG OUTCOME trial
10.2337/dc20-1096 · doi-reference
Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial
10.1007/s11325-022-02594-2 · doi-reference
Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action
10.2337/dc16-1787 · doi-reference
SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: an umbrella review of systematic reviews
10.1136/bmjdrc-2020-001956 · doi-reference